<DOC>
	<DOCNO>NCT01125813</DOCNO>
	<brief_summary>This study determine efficacy human-cl rhFVIII previously treat patient severe hemophilia A prophylactic treatment , treatment bleed episode surgical prophylaxis .</brief_summary>
	<brief_title>Efficacy Safety Study Human-cl rhFVIII PTPs With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( ( FVIII : C &lt; = 1 % ) Male subject &gt; = 12 year age Previously treat FVIII concentrate , least 50 EDs Immunocompetent ( CD4+ count &gt; 200/ul ) Negative anti HIV ; positive , viral load &lt; 200 particles/u ; &lt; 400,000 copies/mL Other coagulation disorder hemophilia A Present past FVIII inhibitor activity ( .= 0.6 BU ) Severe liver kidney disease Receiving schedule receive immunomodulating drug</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>